Pancreatic Cancer Research

ResearcherUniversity of HelsinkiActive in the last 2 years

Annika Eurola

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3013-470X; OpenAlex author ID A5071001503. Sources: OpenAlex.

Their work

Papers
4 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
8
Papers, trials and grants by year

2021: 1 paper · 2022: 2 papers · 2023: none · 2024: none · 2025: 1 paper

Papers 4

  1. The prognostic significance of MMP-8 tissue Immunoexpression in pancreatic ductal adenocarcinoma after neoadjuvant therapy. First author DOI 10.1038/s41598-025-10538-5↗
  2. Preoperative oncologic therapy and the prolonged risk of venous thromboembolism in resectable pancreatic cancer. Co-author DOI 10.1002/cam4.4397↗
  3. β-catenin plus PROX1 immunostaining stratifies disease progression and patient survival in neoadjuvant-treated pancreatic cancer. Co-author DOI 10.3233/tub-211581↗
  4. Impact of histological response after neoadjuvant therapy on podocalyxin as a prognostic marker in pancreatic cancer. Co-author DOI 10.1038/s41598-021-89134-2↗

Closest collaborators

The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hanna E. Seppänen · 4 shared papers, 2021–2025 · strength 0.74
  2. Caj H. Haglund · 4 shared papers, 2021–2025 · strength 0.74
  3. Anna Maria Nurmi · 2 shared papers, 2021–2022 · strength 0.30
  4. Mirjami Kaasinen · 1 shared paper, 2025 · strength 0.25
  5. Ella Kesti · 1 shared paper, 2025 · strength 0.25
  6. Malin Sund · 1 shared paper, 2025 · strength 0.25
  7. Riitta Lassila · 1 shared paper, 2022 · strength 0.19
  8. Nora Mattila · 1 shared paper, 2022 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.